Skip to main content

Thermo Fisher's Acquisition of Dionex Clears Antitrust Waiting Period

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Thermo Fisher Scientific said today that its proposed $2.1 billion acquisition of chromatography firm Dionex has cleared the mandatory, pre-merger waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Thermo said it is in the process of "seeking similar clearances under antitrust laws of other jurisdictions," and expects to complete the acquisition later in the quarter.

The company in December announced plans to acquire Dionex for $118.50 per share in cash, which represented a 21 percent premium to Dionex's closing share price of $98.17 on Dec. 10, the last trading day prior to the announcement.

Dionex shares were trading at $117.95 Monday afternoon.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.